Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA7 | P43166 | 4/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD1 | P21728 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625839 | 0.88 | DRD1 (0.43) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL16625821 | 0.88 | DRD1 (0.43) | MAPTMAPK1CA1CA2CA9 | |
| SCHEMBL16627007 | 0.85 | CA1 (0.52) | CA1CA2CA9CA14CA12 | |
| SCHEMBL16625836 | 0.84 | DRD1 (0.46) | MAPK1CA1CA2CA9CA14 | |
| SCHEMBL16625834 | 0.84 | DRD1 (0.51) | ESR1ESR2DRD2DRD1 | |
| SCHEMBL16625810 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTCA1CA2CA9 | |
| SCHEMBL17342925 | 0.80 | CA1 (0.51) | ALDH1A1MAPTMAPK1CA1CA2 | |
| SCHEMBL16625802 | 0.71 | USP2 (0.47) | ALDH1A1DRD2DRD1 | |
| SCHEMBL16625813 | 0.71 | USP2 (0.47) | ALDH1A1DRD2DRD1 | |
| SCHEMBL16627015 | 0.71 | CA1 (0.54) | MAPK1CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181237-B2 | Substituted berbines and their synthesis | MALLINCKRODT LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | SUCAMPO PHARMA AMERICAS LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099772-A1 | SUBSTITUTED BERBINES AND THEIR SYNTHESIS | TYMS, NME2, TYMP | ALDH1A1 1744/4885MAPT 3210/4885MAPK1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.